SEOUL, KOREA, April 2 – ViroMed Co., Ltd. (KOSDAQ: 084990:KS) today announced that it presented results from the multinational Phase I/II clinical trials on its lead product, VM202-DPN, at 2012 FPN International Research Symposium on Mar 14.
This year’s FPN International Research Symposium, an annual event hosted by The Foundation for Peripheral Neuropathy (FPN), was held in Chicago from Mar 14 to 16 and featured world renowned experts in the field of peripheral neuropathy. The groundbreaking results of the 1-year follow-up to Phase I/II clinical trial on VM202-DPN were presented by the principal PI of the study, John A. Kessler, MD., of Northwestern Memorial Hospital, Chicago, US. The results of the 6-months follow-up to the same study had been presented last year at BIO KOREA 2011 and received the scientific community’s high regard for the excellent results.
“This clinical trial has confirmed the safety as well as the efficacy of VM202-DPN. Only two injections (at 2-week intervals) produced prolonging pain-reduction effects which were still lasting by the end of the 1-year follow-up period,” said Dr. Jong-Mook Kim, the Director of Clinical Development & Strategic Business. "These results suggest that VM202-DPN possesses the potential to be an innovative disease modifying drug set apart from the pre-existing drugs which are only effective for temporary pain-relief.”
ViroMed received approval for Phase II trial in the US based on these exciting and promising Phase I/II results, and an application for Phase II trials in Korea has been submitted to the Korea FDA. These trials will be conducted as multinational Phase II trials enrolling approx. 100 patients in total, and the first injection is planned in May-Jun.